It’s a Global Crisis: What the Review on Anti-Microbial Resistance Wants to Do About AMR
After collaborating on a series of papers surrounding the growing health concern of drug-resistant infections, the Review on Antimicrobial Resistance released a final report this month, which outlined the steps and interventions this team of experts deems necessary for international progress. The facts and figures detailed within the report are alarming. For example, AMR has been the cause of an estimated 700,000 deaths worldwide in this year alone. This number is projected to rise to 10 million deaths per year by 2050 at a cost of USD $100 trillion to the global economy, if immediate action is not taken.
To avoid getting to that point, the AMR review presented ten recommendations in their latest and final report. These recommendations include (but are not limited to) enacting a global public awareness campaign to bring the imminent health threat of AMR to the attention of the entire society, from the patients who demand antimicrobials to the doctors who prescribe them. Additionally, the Review on Antimicrobial Resistance suggests improving hygiene in general as a manner of preventing further spread of the infections antimicrobials are used to treat, as well as promoting development and use of vaccines or alternative medications to prevent further dependence upon/resistance to antimicrobials.
The report goes on to outline in detail exactly which steps must be taken by international governments as well as key decision-makers in the industries of healthcare, pharma, microbiology, and what the costs and benefits of taking these actions will be. This is the quintessential document for promoting awareness and action among these key players on this global crisis.
The World Anti-Microbial Resistance Congress 2016, held September 8-9 in Washington, DC will address the challenges and objectives faced by those who are working toward tackling antimicrobial resistance. Attend to learn more about this global crisis and what needs to be done to stop it, and hear it from speakers from organizations like the AMR Review, Pew Trust, NIH, BARDA, FDA, CDC, key leaders from pharma and biotechs, and other decision makers in healthcare, academia, and government agencies.